HomeTrialNCT06632600
🔬NCT06632600Phase 2RECRUITING

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

Study Summary

This study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.

Conditions
Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment130 participants
Primary Completion
Lead SponsorNovartis Pharmaceuticals
Data Retrieved2026-04-11 02:55:49.151372+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.